396 related articles for article (PubMed ID: 30957843)
1. Association Between Amyloid-β, Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals.
Nadkarni NK; Tudorascu D; Campbell E; Snitz BE; Cohen AD; Halligan E; Mathis CA; Aizenstein HJ; Klunk WE
J Gerontol A Biol Sci Med Sci; 2019 Oct; 74(11):1753-1760. PubMed ID: 30957843
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
3. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
4. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
5. Association of moderate alcohol intake with in vivo amyloid-beta deposition in human brain: A cross-sectional study.
Kim JW; Byun MS; Yi D; Lee JH; Ko K; Jeon SY; Sohn BK; Lee JY; Kim YK; Shin SA; Sohn CH; Lee DY;
PLoS Med; 2020 Feb; 17(2):e1003022. PubMed ID: 32097439
[TBL] [Abstract][Full Text] [Related]
6. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
7. Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype.
Bangen KJ; Clark AL; Werhane M; Edmonds EC; Nation DA; Evangelista N; Libon DJ; Bondi MW; Delano-Wood L;
J Alzheimers Dis; 2016 Mar; 52(3):849-61. PubMed ID: 27031472
[TBL] [Abstract][Full Text] [Related]
8. Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals.
van der Kall LM; Truong T; Burnham SC; Doré V; Mulligan RS; Bozinovski S; Lamb F; Bourgeat P; Fripp J; Schultz S; Lim YY; Laws SM; Ames D; Fowler C; Rainey-Smith SR; Martins RN; Salvado O; Robertson J; Maruff P; Masters CL; Villemagne VL; Rowe CC
Neurology; 2021 Feb; 96(5):e662-e670. PubMed ID: 33184233
[TBL] [Abstract][Full Text] [Related]
9. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
10. White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration.
Kantarci K; Schwarz CG; Reid RI; Przybelski SA; Lesnick TG; Zuk SM; Senjem ML; Gunter JL; Lowe V; Machulda MM; Knopman DS; Petersen RC; Jack CR
JAMA Neurol; 2014 Dec; 71(12):1547-54. PubMed ID: 25347157
[TBL] [Abstract][Full Text] [Related]
11. Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.
Petersen RC; Wiste HJ; Weigand SD; Rocca WA; Roberts RO; Mielke MM; Lowe VJ; Knopman DS; Pankratz VS; Machulda MM; Geda YE; Jack CR
JAMA Neurol; 2016 Jan; 73(1):85-92. PubMed ID: 26595683
[TBL] [Abstract][Full Text] [Related]
12. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
13. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
14. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
[TBL] [Abstract][Full Text] [Related]
16. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
[TBL] [Abstract][Full Text] [Related]
17. The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies.
Arenaza-Urquijo EM; Przybelski SA; Lesnick TL; Graff-Radford J; Machulda MM; Knopman DS; Schwarz CG; Lowe VJ; Mielke MM; Petersen RC; Jack CR; Vemuri P
Brain; 2019 Apr; 142(4):1134-1147. PubMed ID: 30851100
[TBL] [Abstract][Full Text] [Related]
18. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
[TBL] [Abstract][Full Text] [Related]
19. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.
Jack CR; Wiste HJ; Therneau TM; Weigand SD; Knopman DS; Mielke MM; Lowe VJ; Vemuri P; Machulda MM; Schwarz CG; Gunter JL; Senjem ML; Graff-Radford J; Jones DT; Roberts RO; Rocca WA; Petersen RC
JAMA; 2019 Jun; 321(23):2316-2325. PubMed ID: 31211344
[TBL] [Abstract][Full Text] [Related]
20. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis.
Knopman DS; Jack CR; Wiste HJ; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
JAMA Neurol; 2013 Aug; 70(8):1030-8. PubMed ID: 23797806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
